ABCL
ABCL clinical trials: AbCellera Biologics Inc.
Every trial on ClinicalTrials.gov where AbCellera Biologics Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 2
- As lead sponsor
- 6
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ABCL on the catalyst calendar · ABCL registry changes
- Primary completion Feb 2027Sponsor estimatePhase 1/Phase 2NCT07118891Study Evaluating ABCL635 for Vasomotor Symptoms of MenopauseAbCellera Biologics Inc. · Vasomotor Symptoms Associated With MenopauseActive, not recruitingABCLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 1NCT07108894A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy ParticipantsAbCellera Biologics Inc. · Healthy VolunteersActive, not recruitingABCLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 21, 2023ActualPhase 2/Phase 3NCT04427501A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 IllnessEli Lilly and Company · COVID-19CompletedLLYLeadABCLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT04603651Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19Eli Lilly and Company · COVID-19No longer availableLLYLeadABCLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 27, 2021ActualPhase 2NCT04634409A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 IllnessEli Lilly and Company · COVID-19
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 16, 2021ActualPhase 3NCT04497987A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and...Eli Lilly and Company · COVID-19CompletedLLYLeadABCLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 22, 2021ActualPhase 2NCT04701658A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)Eli Lilly and Company · COVID-19CompletedLLYLeadABCLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 26, 2020ActualPhase 1NCT04411628A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19Eli Lilly and Company · COVID-19CompletedLLYLeadABCLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner